Taken together, our observations point to specific inhibitory effects of ERβ on hormone-dependent breast cancer cell proliferation and also suggest that molecules directly targeting ERα/ERβ interactions or ERβ mimics could be a novel strategy to develop estrogen response modifiers for the management of ERα-positive breast tumors. Here, ESR2 is linked to breast cancer.